Quality of life in Ankylosing Spondylitis (AS): Development of the Patient-reported as Questionnaire (PASQ)

被引：0
|
作者：
Haywood, K. L.
Garratt, A. M.
Packham, J. C.
Fitzpatrick, R.
机构：
[1] RCN Inst, Oxford, England
[2] Nasjonalt Kunnskapssenter Helsetjenesten, Norwegian Ctr Hlth Serv Res, Oslo, Norway
[3] Univ Hosp N Staffs NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent, Staffs, England
[4] Univ Oxford, Dept Publ Hlth & Primary Care, Oxford OX3 7LF, England
来源：
RHEUMATOLOGY | 2006年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I131 / I131
页数：1
相关论文
共 50 条
  • [41] RESPONSIVENESS OF THE EVALUATING ANKYLOSING SPONDYLITIS QUALITY OF LIFE (EASI-QOL) QUESTIONNAIRE
    Packham, Jon
    Jordan, Kelvin P.
    Lebmeier, Max
    Garratt, Andrew M.
    Healey, Emma L.
    Haywood, Kirstie L.
    [J]. RHEUMATOLOGY, 2010, 49 : I57 - I58
  • [42] ADAPTATION AND VALIDATION OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE FOR USE IN SERBIA
    Zlatkovic-Svenda, M. I.
    Radak-Perovic, M. M.
    Milicevic, J.
    Stojanovic, R.
    Lazovic, B.
    Ostojic, P.
    Wilburn, J.
    McKenna, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 856 - 856
  • [43] Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
    M. T. Duruöz
    L. Doward
    Y. Turan
    L. Cerrahoglu
    M. Yurtkuran
    M. Calis
    N. Tas
    S. Ozgocmen
    O. Yoleri
    B. Durmaz
    S. Oncel
    T. Tuncer
    O. Sendur
    M. Birtane
    F. Tuzun
    U. Bingol
    M. Kirnap
    G. Celik Erturk
    O. Ardicoglu
    A. Memis
    F. Atamaz
    R. Kizil
    C. Kacar
    G. Gurer
    K. Uzunca
    H. Sari
    [J]. Rheumatology International, 2013, 33 : 2717 - 2722
  • [44] Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
    Duruoz, M. T.
    Doward, L.
    Turan, Y.
    Cerrahoglu, L.
    Yurtkuran, M.
    Calis, M.
    Tas, N.
    Ozgocmen, S.
    Yoleri, O.
    Durmaz, B.
    Oncel, S.
    Tuncer, T.
    Sendur, O.
    Birtane, M.
    Tuzun, F.
    Bingol, U.
    Kirnap, M.
    Erturk, G. Celik
    Ardicoglu, O.
    Memis, A.
    Atamaz, F.
    Kizil, R.
    Kacar, C.
    Gurer, G.
    Uzunca, K.
    Sari, H.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2013, 33 (11) : 2717 - 2722
  • [45] Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
    Doward, LC
    Spoorenberg, A
    Cook, SA
    Whalley, D
    Helliwell, PS
    Kay, LJ
    McKenna, SP
    Tennant, A
    van der Heijde, D
    Chamberlain, MA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (01) : 20 - 26
  • [46] RESPONSIVENESS TO CHANGE OF THE MULTIDIMENSIONAL PATIENT REPORTED OUTCOME MEASURES QUESTIONNAIRE FOR PATIENTS WITH ANKYLOSING SPONDYLITIS/SPONDYLOARTHRITIS
    El Miedany, Yasser
    El Gaafary, Maha
    Youssef, Sally
    Palmer, Deborah
    [J]. RHEUMATOLOGY, 2010, 49 : I50 - I50
  • [47] Function in patients with ankylosing spondylitis is the resultante of patient-reported disease activity and radiographic damage of the spine
    Landewé, RBM
    Wanders, A
    Mielants, H
    Dougados, M
    Van der Heijde, D
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 98 - 99
  • [48] Five-year efficacy and safety, including patient-reported outcomes, with etanercept in ankylosing spondylitis
    Mola, E. Martin
    van der Linden, S.
    Wishneski, C.
    Robertson, D.
    Freundlich, B. F.
    Koenig, A. S.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S584 - S585
  • [49] The profile of the Romanian patient with ankylosing spondylitis and the impact of the disease on quality of life
    Udrea, G
    Stoica, V
    Bolosiu, H
    Chiriac, R
    Rezus, E
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 561 - 561
  • [50] Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire
    Schreuder, Nanno
    de Hoog, Quincy
    de Vries, Sieta T.
    Jager, Pieter L.
    Kosterink, Jos G. W.
    van Puijenbroek, Eugene P.
    [J]. DRUG SAFETY, 2020, 43 (04) : 319 - 328
12345